Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | PPID | Q08752 | 3/20 | 0.56 |
| ▸ | PPIB | P23284 | 2/20 | 0.56 |
| ▸ | PPIA | P62937 | 1/20 | 0.56 |
| ▸ | PPIG | Q13427 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7441659 | 0.98 | CYP2C9 (0.60) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL20497326 | 0.94 | CYP1A2 (0.56) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL11533429 | 0.91 | CYP2C9 (0.65) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| Alanine SCHEMBL22445734 | 0.87 | ITGB1 (0.51) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL15939528 | 0.86 | PPID (0.65) | CYP2C9CYP2C19PPIDPPIBPPIA | |
| SCHEMBL20705214 | 0.85 | CYP2C19 (0.61) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL972153 | 0.85 | PPID (0.55) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL4738233 | 0.84 | CYP2C9 (0.85) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL1919932 | 0.84 | EPHX2 (0.53) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL8245710 | 0.84 | CYP2C9 (0.68) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 987 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| US-12606830-B2 | Protected antibody-drug and aptamer-drug conjugates | KOSAK KENNETH MICHAEL (US) | 2026-04-21 | — | — | US | claimed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | claimed |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | LONZA SALES AG (CH) | 2026-01-29 | — | — | US | claimed |
| EP-4676540-A1 | PANRAS INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2026-01-14 | — | — | EP | claimed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | claimed |
| US-20250382613-A1 | METHODS OF USING EXTRACELLULAR VESICLE-ASO TARGETING STAT6 | LONZA SALES AG (CH) | 2025-12-18 | — | — | US | claimed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | claimed |
| EP-4642491-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | Honeybear Biosciences Inc. (TW) | 2025-11-05 | — | — | EP | claimed |
| WO-2025202361-A1 | ANTI-GPC1 ANTIBODIES AND USES THEREOF | ADCENDO APS (DK) | 2025-10-02 | — | — | WO | claimed |
| EP-2710024-A2 | OSW-1 ANALOGS AND CONJUGATES, AND USES THEREOF | President and Fellows of Harvard College (US) | 2014-03-26 | — | — | EP | claimed |
| EP-1912677-B1 | PSMA antibody-drug conjugates | PSMA DEV COMPANY L L C (US) | 2013-10-02 | — | — | EP | claimed |
| EP-2326350-B1 | COMPOUNDS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | PSMA DEV COMPANY L L C (US) | 2013-09-04 | — | — | EP | claimed |
| WO-2012159027-A2 | OSW-1 ANALOGS AND CONJUGATES, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-11-22 | — | — | WO | claimed |
| EP-2326350-A2 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | Psma Development Company, L.L.C. (US) | 2011-06-01 | — | — | EP | claimed |
| WO-2010027513-A2 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | PSMA DEVELOPMENT COMPANY, LLC (US) | 2010-03-11 | — | — | WO | claimed |
| EP-1912677-A2 | PSMA ANTIBODY-DRUG CONJUGATES | Psma Development Company, L.L.C. (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007002222-A2 | PSMA ANTIBODY-DRUG CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2007-01-04 | — | — | WO | claimed |
| US-6214345-B1 | ANTITUMOR AGENTS; DRUG CONJUGATES WHICH ARE SELECTIVELY ACTIVATIBLE AT THE SITE OF THE TUMOR | BRISTOL-MYERS SQUIBB CO. | 2001-04-10 | — | — | US | claimed |
| US-5480989-A | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-01-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | CYP2C9 2939/4885CYP2C19 3919/4885CYP1A2 3146/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | CYP2C9 3660/4885CYP2C19 4171/4885CYP1A2 3981/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | CYP2C9 2470/4885CYP2C19 3055/4885CYP1A2 4499/4885 |
| US-20250382613-A1 | METHODS OF USING EXTRACELLULAR VESICLE-ASO TARGETING STAT6 | STAT6, EXOSC5, STAT5B | CYP2C9 4881/4885CYP2C19 4885/4885CYP1A2 4884/4885 |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CEBPZ, OSBP, DIS3 | CYP2C9 4821/4885CYP2C19 4884/4885CYP1A2 4876/4885 |
| US-12606830-B2 | Protected antibody-drug and aptamer-drug conjugates | PABPC1, PABPC4, ABCG2 | CYP2C9 2431/4885CYP2C19 3366/4885CYP1A2 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.